Degarelix

FDA approved

Degarelix (Firmagon) is a GnRH receptor antagonist approved by the FDA in 2008 for advanced prostate cancer. Unlike leuprolide, it lowers testosterone immediately without an initial surge.

At a glance

Where it acts: Sexual & reproductive
Regulatory status: FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Degarelix is a synthetic 10-amino acid peptide that blocks pituitary GnRH receptors directly, rapidly reducing LH, FSH and testosterone without the hormone flare seen with GnRH agonists.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

Injection site reactions (very common), hot flashes, weight gain, fatigue and raised liver enzymes.

QT prolongation, bone loss, and metabolic and cardiovascular effects of androgen deprivation.

Who Uses Degarelix

Men with advanced prostate cancer.